^
Association details:
| Biomarker: | CDKN2A mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | adavosertib (AZD1775) (WEE1 inhibitor) + VIC-1911 (Aurora kinase A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract 604: Combination of the Aurora A inhibitor TAS-119 and adavosertib results in synergistic c-Jun-mediated cell death in head and neck and lung cancers
Published date:
05/15/2020
Excerpt:
TAS119 and adavosertib combination treatment synergistically suppressed cell viability, clonogenic cell survival, anchorage-independent cell growth in soft agar and oncosphere formation relative to vehicle and single-agent treatment in HNSCC FaDu and CAL27 cells, and lung cancer NCI-H520 and NCI-H358 cells bearing TP53/CDKN2A mutations.
DOI:
10.1158/1538-7445.AM2020-604
